Navigation Links
OncoSec Medical Reports Third Quarter 2011 Financial Results
Date:6/15/2011

utic agents and nucleic acids encoding cytokines for the treatment of solid tumors. Pursuant to the agreement, OncoSec made an upfront payment of $250,000 and will pay up to an additional amount of $2.75M by March 24, 2013, based on achievement of milestones. OncoSec will also pay Inovio royalties based on commercial product sales.

Clinical Development

OncoSec announced that it will initiate three Phase II clinical trials to evaluate its lead ElectroImmunotherapy technology, DNA IL-12 locally delivered using electroporation, in patients with melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma. The company is building on positive Phase I dose-escalation trial results in 24 patients with metastatic melanoma. This previous study demonstrated that treatment with DNA IL-12 in conjunction with electroporation was safe and well tolerated, and suggested a systemic objective response in more than half of the subjects, 15% of patients showing 100% clearance of distant, untreated tumors. Each respective trial will be run under a physician-sponsored IND. These studies are expected to start before the end of 2011.

About OncoSec Medical Inc.

OncoSec Medical (OTCBB: ONCS) develops novel ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec's clinical programs include three Phase II clinical trials. More information is available at www.oncosec.com.

This press release contains forward looking statements within the meaning of th
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoSec Medical Appoints Punit Dhillon as President and CEO
2. OncoSec Medical Featured in Medical Device Daily
3. OncoSec Announces Leadership Team Appointments
4. OncoSec Announces Clinical Leadership Appointments
5. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
6. Inverness Medical Innovations Features Innovative TB Diagnostic - Clearview(R) TB ELISA at AIDS 2008
7. ICON Medical Imaging Launches New Service to Boost Reliability of Cardiology Studies
8. Informed Medical Communications Highlights Opportunity in Revised PhRMA Code
9. Concentric Medical(R) Announces Co-Marketing Agreement With InTouch Health(R) to Advance Acute Ischemic Stroke Care
10. BioMS Medical Announces Second Quarter 2008 Results
11. ATS Medical to Participate at the Fourth Annual Noble Financial Equity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Investor-Edge has initiated coverage on ... Medivation Inc. (NASDAQ: MDVN ), Pharmacyclics Inc. ... MKT: SYN), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). Free ... http://investor-edge.com/register . On Wednesday, October 29, ... the Dow Jones Industrial Average declined 0.18%, to finish ...
(Date:10/30/2014)... SoundConnect , an industry leading ... end users the key to turning this already ... adding voice enablement and hybrid audio conferencing. , ... communication tool that includes presence, instant messaging and ... becomes a comprehensive unified communications solution. Adding the ...
(Date:10/30/2014)... Avure Technologies celebrates a year of success and ... its fleet of high volume High Pressure Processing (HPP) systems. ... return to PackExpo this year, which is where we first ... Jeff Williams, CEO at Avure. “Sales of the new Avure ... meeting the challenges of market demand for higher throughput. We ...
(Date:10/30/2014)... in the development of quantum technologies has been proposed ... published today (28 October) in Nature Communications , ... a new type of flexibly designed microscopic trap for ... and specialised superfast computers, often depend on harnessing the ... these tiny particles are hugely problematic because of the ...
Breaking Biology Technology:Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 2Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 3Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 4Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 5SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3
... DALLAS, October 14, 2010 ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... Inc., a global leader in the research and development of ... its 2010 UCB Crohn,s and Me Scholarship Program ... 31 winners to receive a scholarship worth up to $10,000 ... The scholarship winners include Crohn,s disease patients, ...
... Kenya and Uganda have laid the groundwork for confined ... varieties of maize genetically modified to survive recurrent droughts ... is life, according to a speech given today by ... at the World Food Prize Symposium. Scientists working ...
Cached Biology Technology:The World Market for Diabetes Treatments Now Available at ReportsandReports 2The World Market for Diabetes Treatments Now Available at ReportsandReports 3The World Market for Diabetes Treatments Now Available at ReportsandReports 4The World Market for Diabetes Treatments Now Available at ReportsandReports 5The World Market for Diabetes Treatments Now Available at ReportsandReports 6The World Market for Diabetes Treatments Now Available at ReportsandReports 7The World Market for Diabetes Treatments Now Available at ReportsandReports 8The World Market for Diabetes Treatments Now Available at ReportsandReports 92010 UCB Crohn's and Me Scholarship Winners Announced 22010 UCB Crohn's and Me Scholarship Winners Announced 32010 UCB Crohn's and Me Scholarship Winners Announced 4Scientists prepare for confined field trials of life-saving drought-tolerant transgenic maize 2Scientists prepare for confined field trials of life-saving drought-tolerant transgenic maize 3
(Date:10/29/2014)... China — BGI Tech and Hebei Agricultural University jointly ... genome. Jujube is the most economically important member of ... difficult to sequence due the high level of heterozygosity ... that a genome in the Rhamnaceae (Buckthorn) family has ... Nature Communications . , Jujube is ...
(Date:10/29/2014)... new study on a large cohort of kidney cancer ... of the disease -- and reveals an apparent link ... cancer, particularly in Romania. , The research, by an ... and Genome Quebec Innovation Centre in Montreal, underscores the ... acid. The compound, found in plants of the Aristolochia ...
(Date:10/28/2014)... to expand the Office of Rare Diseases Research ... Sciences (ORDR-NCATS) collaborative Rare Diseases Clinical Research Network ... 22 consortia will work with 98 patient advocacy ... treatments for patients with rare diseases. The collaborations ... 2014 funding from NIH. , Rett syndrome, MECP2 ...
Breaking Biology News(10 mins):BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree 2Study sheds light on genetic architecture of kidney cancer 2Study sheds light on genetic architecture of kidney cancer 3NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3
... sapiens migrating out of Africa began encountering Neanderthals, ... of thousands of years before. Despite their differences, ... produced children with genes from both lineages. Today, the ... remain alive in the genomes of humans with European ...
... a single gene in honey bees separates the queens from ... University and Wayne State University unraveled the gene,s inner workings ... Biology Letters . The gene, which is responsible for leg ... of bees, ability to carry pollen. "This gene is ...
... provider of scientific, technical and medical information products ... journal, Pathogenesis . Pathogenesis ... College of Pathologists a professional membership organization committed ... excellence in the practice of Pathology. The College ...
Cached Biology News:When populations collide 2When populations collide 3When populations collide 4Single gene separates queen from workers 2Elsevier announces the launch of open access journal: Pathogenesis 2
ERalpha (Ser 104/106)...
... Phosphatase, Calf Intestinal (CIAP), catalyzes the hydrolysis ... ribo- and deoxyribonucleoside triphosphates. This enzyme is ... linearized cloning vector DNA by removing phosphate ... be used for the dephosphorylation of 5 ...
Mouse CXCR3 Allophycocyanin MAb (Clone 220803)...
Homo sapiens palladin...
Biology Products: